ONCOLOGY INSTITUTE INC/THE (TOI)
US68236X1000 - Common Stock
Overall TOI gets a fundamental rating of 3 out of 10. We evaluated TOI against 109 industry peers in the Health Care Providers & Services industry. TOI has a bad profitability rating. Also its financial health evaluation is rather negative. TOI shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year TOI has reported negative net income.
TOI had a negative operating cash flow in the past year.
TOI had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: TOI reported negative operating cash flow in multiple years.
1.2 Ratios
TOI has a worse Return On Assets (-32.07%) than 85.19% of its industry peers.
TOI has a Return On Equity of -371.14%. This is amonst the worse of the industry: TOI underperforms 84.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.07% | ||
| ROE | -371.14% | ||
| ROIC | N/A |
ROA(3y)-12.59%
ROA(5y)-13.25%
ROE(3y)-43.14%
ROE(5y)-37.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of TOI (14.18%) is worse than 75.00% of its industry peers.
In the last couple of years the Gross Margin of TOI has declined.
The Profit Margin and Operating Margin are not available for TOI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.26%
GM growth 5Y-4.59%
2. Health
2.1 Basic Checks
TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TOI has been increased compared to 1 year ago.
TOI has a worse debt/assets ratio than last year.
2.2 Solvency
TOI has an Altman-Z score of -0.08. This is a bad value and indicates that TOI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.08, TOI is doing worse than 75.00% of the companies in the same industry.
TOI has a Debt/Equity ratio of 5.91. This is a high value indicating a heavy dependency on external financing.
TOI's Debt to Equity ratio of 5.91 is on the low side compared to the rest of the industry. TOI is outperformed by 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.91 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.08 |
ROIC/WACCN/A
WACC5.94%
2.3 Liquidity
A Current Ratio of 2.49 indicates that TOI has no problem at all paying its short term obligations.
TOI has a better Current ratio (2.49) than 82.41% of its industry peers.
TOI has a Quick Ratio of 2.27. This indicates that TOI is financially healthy and has no problem in meeting its short term obligations.
TOI has a Quick ratio of 2.27. This is amongst the best in the industry. TOI outperforms 80.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.49 | ||
| Quick Ratio | 2.27 |
3. Growth
3.1 Past
TOI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.85%.
TOI shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.29%.
The Revenue has been growing by 23.43% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
Revenue 1Y (TTM)22.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.43%
Sales Q2Q%21.78%
3.2 Future
The Earnings Per Share is expected to grow by 32.88% on average over the next years. This is a very strong growth
Based on estimates for the next years, TOI will show a very strong growth in Revenue. The Revenue will grow by 22.73% on average per year.
EPS Next Y38.52%
EPS Next 2Y32.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.38%
Revenue Next 2Y22.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TOI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TOI's earnings are expected to grow with 32.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.88%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for TOI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ONCOLOGY INSTITUTE INC/THE
NASDAQ:TOI (12/18/2024, 7:49:23 PM)
After market: 0.183 0 (-1.72%)0.1862
0 (-2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.07M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.07% | ||
| ROE | -371.14% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.18% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.91 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.49 | ||
| Quick Ratio | 2.27 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y38.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.29%
Revenue growth 3Y20.03%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y